Subscribe to magazine
Subscribe to newsletters
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Radiation Dose management
Intravascular imaging systems
Peripheral Artery Disease
Leads, implantable devices
Implantable cardioverter defibrillators (ICD)
Cardiac resynchronization therapy devices (CRT)
Heart Valve Technology
Left atrial appendage (LAA) occluders
Structural heart occluders/closure devices
Clinical decision support
1145 Terra Bella Avenue, Suite A
Mountain View, California 94043
June 06, 2016
Amaranth Medical Completes Enrollment in RENASCENT-II Study
Amaranth Medical announced that it completed enrollment in May in the RENASCENT-II study of its novel Aptitude 120-...
October 16, 2015
Amaranth Medical Completes Two Studies, Initiates Third for its and Sirolimus-Eluting Bioresorbable Scaffold
October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials M
Image courtesy of Amaranth Medical
May 21, 2015
Amaranth Medical Reports Data for Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015
Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation...
October 07, 2014
Amaranth Starts Clinical Trial of Fortitude
Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical...
January 14, 2014
Boston Scientific Invests in Bioresorbable Stent Startup Amaranth Medical
Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp.
October 31, 2013
Amaranth Medical Reports Positive Safety, Feasibility for the Fortitude Bioresorbable Scaffold
Amaranth Medical, a privately held medical device company, presented positive six-month angiographic results from its...
Scranton Gillette Communications
. All Rights Reserved.